YOLFTbeta
Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

EWL · XETRA · Healthcare / Medical Devices

97.26EUR+1.62 (+1.69%)

Price History

Full chart

Market Stats

Previous Close95.64
Open96.52
Day Range95.54 – 97.26
52-Week Range63.38 – 84.00
Volume54
Market Cap44.00B
P/E (TTM)50.89
Forward P/E26.25
EPS1.50
Dividend Yield0.00%
Beta0.85
50-Day Avg76.92
200-Day Avg73.38

About

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Bernard J. Zovighian
  • Employees16.00K
  • HeadquartersOne Edwards Way, Irvine, CA, United States, 92614, Germany
  • Websitehttps://www.edwards.com

Leadership

  • Mr. Bernard J. ZovighianCEO & Director · b. 1968
  • Mr. Donald E. Bobo Jr.Corporate Vice President of Strategy & Corporate Development · b. 1962
  • Mr. Daveen ChopraCorporate Vice President of Transcatheter Mitral & Tricuspid Therapies · b. 1979
  • Ms. Annette Maria BrulsCorporate Vice President of EMEA, Canada, & Latin America · b. 1971
  • Ms. Theodora MistrasCorporate VP & CFO · b. 1982
  • Mr. Joseph NuzzoleseCorporate Vice President of Global Operations & Quality
  • Mr. Andrew M. DahlPrincipal Accounting Officer, Senior VP & Corporate Controller · b. 1978
  • Dr. Todd Brinton FACC, M.D.Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer
  • Mr. Snehashish SarkarSenior VP and Chief Information & Digital Officer · b. 1975
  • Mr. Mark D. PetersonCorporate VP & General Counsel · b. 1963

Financials

Income Statement

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.23B4.46B5.01B5.44B6.07B
Growth (%)--14.69%+12.23%+8.57%+11.55%
Cost of Revenue1.25B723.70M978.40M1.12B1.33B
Gross Profit3.98B3.74B4.03B4.32B4.73B
Gross Margin76.13%83.79%80.47%79.46%78.01%
Operating Expense2.40B2.20B2.55B2.84B3.10B
Operating Income1.59B1.54B1.49B1.48B1.64B
Operating Margin30.33%34.48%29.66%27.21%26.97%
EBITDA-1.68B1.53B1.72B1.45B
EBITDA Margin-37.60%30.64%31.68%23.90%
Net Income1.50B1.52B1.40B4.17B1.07B
Net Income Margin28.73%34.09%27.99%76.75%17.69%
R&D903.10M843.60M962.90M1.05B1.08B
R&D as % of Total Revenue17.26%18.90%19.22%19.36%17.79%
Interest Expense18.40M19.20M17.60M19.80M20.40M
Interest Expense % of Total Revenue0.35%0.43%0.35%0.36%0.34%

Balance Sheet

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets8.50B8.29B9.36B13.06B13.70B
Total Liabilities2.67B2.49B2.64B2.99B3.36B
Total Equity5.84B5.81B6.65B10.00B10.34B
Cash862.80M769.00M1.13B3.05B2.94B

Cash Flow

Currency: USD2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.73B1.22B895.80M542.30M1.60B
Financing Cash Flow-356.30M-1.58B-711.00M-983.00M-956.80M
Capital Expenditure329.80M264.80M266.30M282.40M260.20M
Free Cash Flow1.40B953.40M629.50M259.90M1.33B
FCF to OCF80.96%78.26%70.27%47.93%83.69%

Earnings

Report DateMar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jul 23, 2026Oct 29, 2026
EPS Estimate---------------------0.740.74
EPS Actual0.440.650.460.460.530.610.550.630.520.460.580.570.540.564.680.610.580.500.430.130.560.36-
Surprise----------------------51.32%-
Timing---------------------After-hoursAfter-hours

Key Statistics & Ratios

Market Cap44.00B
Enterprise Value41.26B
Trailing P/E50.89
Forward P/E26.25
PEG Ratio1.89
Price / Sales6.75
Price / Book4.82
EPS1.50
Book Value16.17
Revenue (TTM)6.51B
Gross Profit (TTM)5.07B
EBITDA2.00B
Profit Margin15.43%
Operating Margin29.84%
Return on Equity9.18%
Return on Assets8.37%
Shares Outstanding576.40M
Shares Float574.49M
Beta0.85
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%